Asthma-chronic obstructive pulmonary disease overlap syndrome: a controversial concept.

Curr Opin Allergy Clin Immunol

aDepartamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay bCentro de Alergia, Inmunología y Enfermedades Respiratorias, Santa Fe, Argentina cDepartment of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomédica Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Department of Medicine, Barcelona, Spain.

Published: February 2017

Purpose Of Review: To illustrate the scant evidence and the shortcomings of the concept of 'asthma-COPD overlap syndrome' (ACOS) in terms of clinical utility.

Recent Findings: Asthma and chronic obstructive pulmonary disease (COPD) are considered as two distinct and heterogeneous diseases. For many years, physicians have been aware that asthma and COPD can coexist in some patients. Recently, the term ACOS has been applied when a person has clinical features of both asthma and COPD. However, the lack of an accurate diagnosis has led to inconsistent data regarding reported prevalence, prognosis and therapeutics. Even today, it has not been possible to establish a phenotypic characterization of ACOS, although it is part of the overall complexity and heterogeneity of COPDs. No high quality data exist on which to base treatment recommendations for ACOS. Consequently, in clinical practice, treatment is extrapolated from the available evidence on asthma and COPD.

Summary: The current concept of ACOS seems clinically irrelevant because it has no influence on the prognosis and treatment of these patients. The authors concluded that the term ACOS should be avoided in the case of patients with features of both asthma and COPD.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ACI.0000000000000326DOI Listing

Publication Analysis

Top Keywords

asthma copd
12
obstructive pulmonary
8
pulmonary disease
8
term acos
8
features asthma
8
acos
6
asthma
5
asthma-chronic obstructive
4
disease overlap
4
overlap syndrome
4

Similar Publications

Background: Chronic respiratory diseases (CRD) represents a series of lung disorders and is posing a global health burden. Systemic inflammation and phenotypic ageing have been respectively reported to associate with certain CRD. However, little is known about the co-exposures and mutual associations of inflammation and ageing with CRD.

View Article and Find Full Text PDF

IRAK4: potential therapeutic target for airway disease exacerbations.

Trends Pharmacol Sci

January 2025

Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, 89 French Street, Suite 4210, New Brunswick, NJ 08901, USA. Electronic address:

Inflammatory lung diseases represent a significant healthcare burden. There is an unmet need for identifying therapeutic targets for inflammatory lung diseases, such as asthma, and chronic obstructive pulmonary disease (COPD). In a recent study, Sayers et al.

View Article and Find Full Text PDF

Advances in applications of the CRISPR/Cas9 system for respiratory diseases.

Prog Mol Biol Transl Sci

January 2025

Graduate School of Biomedical Science and Engineering, Hanyang University, Seoul, Korea; College of Medicine, Hanyang University, Seoul, Korea. Electronic address:

Genetic and environmental factors can have an impact on lung and respiratory disorders which are associated with severe symptoms and have high mortality rates. Many respiratory diseases are significantly influenced by genetic or epigenetic factors. Gene therapy offers a powerful approach providing therapeutic treatment for lung diseases.

View Article and Find Full Text PDF

Silibinin alleviates house dust mite induced allergic airway inflammation by inhibiting NLRC4 inflammasome and MMP-9 expression.

Biomed Pharmacother

January 2025

College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, 77 Yong-bong-ro, Buk-gu, Gwangju 61186, Republic of Korea. Electronic address:

Silibinin, a major compound of silymarin, has been reported to alleviate respiratory diseases including acute lung injury, asthma, chronic obstructive pulmonary disease, and pulmonary fibrosis through its antifibrotic, anti-inflammatory, and antioxidant properties. However, the specific mechanisms underlying its therapeutic effects, particularly in allergic asthma, are not fully understood. With the increasing prevalence and impact of allergic asthma, there is a need to elucidate the exact underlying mechanisms of its potential treatment effects.

View Article and Find Full Text PDF

Thymic stromal lymphopoietin (TSLP) is an alarmin cytokine activated by allergens, pathogens, and air pollutants. Recent studies suggest TSLP dysregulation in chronic inflammatory diseases. It was highlighted as a key player in the context of asthma-associated mucosal immunity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!